Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
02/13/2017 02/14/2017 02/15/2017 02/16/2017 02/17/2017 Date
29.875(c) 29.625(c) 30.875(c) 30.75(c) 32(c) Last
106 579 297 411 287 273 144 179 344 309 Volume
-1.24% -0.84% +4.22% -0.40% +4.07% Change
More quotes
Financials ( GBP)
Sales 2017 15,3 M
EBIT 2017 -37,6 M
Net income 2017 -32,2 M
Finance 2017 10,1 M
Yield 2017 -
Sales 2018 42,1 M
EBIT 2018 -20,1 M
Net income 2018 -11,6 M
Finance 2018 8,64 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 10,4x
EV / Sales2018 3,80x
Capitalization 168 M
More Financials
Company
Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom. 
Sector
Biotechnology & Medical Research
Calendar
02/21 | 08:00amEarnings Release
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
02/16VERNALIS PLC : half-yearly earnings release
02/15 CORVUS PHARMACEUTICALS,INC. (NASDAQ : CRVS) Files An 8-K Other Events
02/14 VERNALIS : Gets USD3 Million Milestone Payment Under Corvus Deal
02/14 VERNALIS : achieves a $3 million milestone payment from Corvus Pharmaceuticals I..
01/31 VERNALIS : Notice of Results for the Six Months Ended 31 December 2016
01/30 VERNALIS PLC : Notice of Results for Six Months Ended 31/12/2016
01/30 VERNALIS : Notice of Results for the Six Months Ended 31 December 2016
2016 VERNALIS : Says US FDA Accepts CCP-08 Cough Drug For Full Review
2016 VERNALIS : FDA accepts CCP-08 NDA for full review
2016 VERNALIS PLC : FDA accepts CCP-08 NDA for full review
More news
Sector news : Biotechnology & Medical Research - NEC
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/15Vernalis plc's buy rating reiterated at Panmure Gordon. GBX 65 PT.  
02/14Vernalis PLC Achieves A $3 Million Milestone Payment From Corvus Pharma  
02/14Vernalis plc's buy rating reiterated at Stifel Nicolaus. GBX 104 PT.  
02/14Vernalis plc's buy rating reiterated at Canaccord Genuity. GBX 88 PT.  
01/30Vernalis PLC: Notice Of Results For Six Months Ended 31/12/2016  
More tweets
Qtime:5
News from SeekingAlpha
2016 Vernalis reports FY16 results
2016 Vernalis ADR reports 6M'15 results
2015 Vernalis acquires U.S. rights to extended-release antibiotic
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,80  GBP
Spread / Average Target 150%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Sandford Sommer President & Chief Operating Officer
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Pascal Borderies Senior Vice President-Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-5.88%209
INCYTE CORPORATION20.17%22 822
QUINTILES IMS HOLDINGS..0.92%18 894
CELLTRION, INC.--.--%10 747
LONZA GROUP AG1.87%10 368
SEATTLE GENETICS, INC.24.12%9 272
More Results